• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用树突状细胞治疗多发性骨髓瘤的免疫疗法：如何改进？

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

作者信息

Nguyen-Pham Thanh-Nhan, Lee Yoon-Kyung, Kim Hyeoung-Joon, Lee Je-Jung

机构信息

Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo 519-763, Republic of Korea.

出版信息

Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15.

DOI:10.1155/2012/397648
PMID:22481968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3312256/
Abstract

Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM.

摘要

多发性骨髓瘤（MM）是一种适合应用细胞免疫疗法的理想靶疾病，该疗法基于移植物抗骨髓瘤效应。免疫效应细胞的这一作用为开发基于免疫的治疗方案提供了框架，这些方案在MM中使用具有更强效力的抗原呈递细胞（APC），如树突状细胞（DC）。目前，分离的独特型（Id）、骨髓瘤细胞裂解物、骨髓瘤死亡细胞、DC-骨髓瘤杂交细胞或用肿瘤衍生RNA转染的DC已用于DC免疫治疗。骨髓瘤细胞产生的免疫抑制细胞因子，如转化生长因子-β（TGF-β）、白细胞介素-10（IL-10）、白细胞介素-6（IL-6）和血管内皮生长因子（VEGF），可通过信号转导和转录激活因子3（STAT3）的组成性激活来调节抗肿瘤宿主免疫反应，包括废除DC功能。因此，尽管在临床试验中观察到了免疫反应，但MM患者接受DC疫苗接种后临床反应很少得到改善。我们将讨论如何提高MM中DC疫苗接种的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/940faa8f05b0/CDI2012-397648.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/e1afc2cf2f5a/CDI2012-397648.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/6e1af3c69a33/CDI2012-397648.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/940faa8f05b0/CDI2012-397648.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/e1afc2cf2f5a/CDI2012-397648.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/6e1af3c69a33/CDI2012-397648.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403f/3312256/940faa8f05b0/CDI2012-397648.003.jpg

相似文献

1
Immunotherapy using dendritic cells against multiple myeloma: how to improve?使用树突状细胞治疗多发性骨髓瘤的免疫疗法：如何改进？
Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15.
2
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.优化树突状细胞疫苗用于多发性骨髓瘤的免疫治疗：肿瘤裂解物比独特型蛋白作为肿瘤抗原更有效，能促进抗肿瘤免疫。
Clin Exp Immunol. 2012 Nov;170(2):167-77. doi: 10.1111/j.1365-2249.2012.04642.x.
3
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.优化树突状细胞为基础的多发性骨髓瘤免疫治疗：腔内注射针对独特型的 CD40L 成熟疫苗可诱导患者产生 1 型和细胞毒性 T 细胞免疫应答。
Br J Haematol. 2010 Sep;150(5):554-64. doi: 10.1111/j.1365-2141.2010.08286.x. Epub 2010 Jul 7.
4
DC in multiple myeloma immunotherapy.树突状细胞在多发性骨髓瘤免疫治疗中的作用
Cytotherapy. 2004;6(2):128-37. doi: 10.1080/14653240410005357.
5
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.自体独特型致敏树突状细胞瘤苗免疫治疗期Ⅰ多发性骨髓瘤患者的细胞免疫应答
J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48.
6
Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.树突状细胞生物学及其在多发性骨髓瘤免疫治疗中的应用。
Med Oncol. 2000 Feb;17(1):2-15. doi: 10.1007/BF02826210.
7
B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.在小鼠中，由树突状细胞进行独特型疫苗接种诱导的B细胞淋巴瘤和骨髓瘤保护作用完全由T细胞介导。
J Immunother. 2005 Sep-Oct;28(5):461-6. doi: 10.1097/01.cji.0000171312.16171.77.
8
Dendritic cells in clinical trials for multiple myeloma.用于多发性骨髓瘤临床试验的树突状细胞。
Methods Mol Med. 2005;109:127-36. doi: 10.1385/1-59259-862-5:127.
9
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.自体外周血干细胞移植后使用树突状细胞进行独特型疫苗接种治疗多发性骨髓瘤——一项可行性研究
Blood. 1999 Apr 1;93(7):2411-9.
10
Optimizing dendritic cell-based immunotherapy in multiple myeloma.优化基于树突状细胞的多发性骨髓瘤免疫疗法。
Br J Haematol. 2002 May;117(2):297-305. doi: 10.1046/j.1365-2141.2002.03411.x.

引用本文的文献

1
Therapeutic strategies to enhance immune response induced by multiple myeloma cells.增强多发性骨髓瘤细胞诱导免疫反应的治疗策略。
Front Immunol. 2023 May 18;14:1169541. doi: 10.3389/fimmu.2023.1169541. eCollection 2023.
2
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.树突状细胞为基础的多发性骨髓瘤免疫治疗：挑战、机遇和未来方向。
Int J Mol Sci. 2022 Jan 14;23(2):904. doi: 10.3390/ijms23020904.
3
The Cancer-Immunity Cycle in Multiple Myeloma.多发性骨髓瘤中的癌症-免疫循环

本文引用的文献

1
Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?树突状细胞与恶性浆细胞：多发性骨髓瘤肿瘤进展中的联盟？
Oncologist. 2011;16(7):1040-8. doi: 10.1634/theoncologist.2010-0327. Epub 2011 Jun 9.
2
Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma.自然杀伤细胞刺激树突状细胞诱导多发性骨髓瘤患者骨髓瘤特异性细胞毒性 T 淋巴细胞反应。
Leuk Res. 2011 Sep;35(9):1241-7. doi: 10.1016/j.leukres.2011.03.032. Epub 2011 May 25.
3
Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.
Immunotargets Ther. 2021 Jul 16;10:247-260. doi: 10.2147/ITT.S305432. eCollection 2021.
4
Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.免疫特征分析对多发性骨髓瘤患者生存的预测作用。
Front Immunol. 2021 Jul 5;12:663748. doi: 10.3389/fimmu.2021.663748. eCollection 2021.
5
Boosting Immunity against Multiple Myeloma.增强对多发性骨髓瘤的免疫力。
Cancers (Basel). 2021 Mar 11;13(6):1221. doi: 10.3390/cancers13061221.
6
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.树突状细胞疗法联合泊马度胺和程序性死亡配体 1 阻断在多发性骨髓瘤临床前模型中的强效抗骨髓瘤疗效。
Cancer Immunol Immunother. 2021 Jan;70(1):31-45. doi: 10.1007/s00262-020-02654-0. Epub 2020 Jul 4.
7
Superparamagnetic iron oxide nanoparticles (SPIONs) as a multifunctional tool in various cancer therapies.超顺磁性氧化铁纳米颗粒（SPIONs）作为一种多功能工具应用于各种癌症治疗中。
Rep Pract Oncol Radiother. 2019 Jul-Aug;24(4):307-314. doi: 10.1016/j.rpor.2019.04.002. Epub 2019 May 20.
8
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?多发性骨髓瘤的免疫疗法：转化小鼠模型如何提供帮助？
J Oncol. 2019 Apr 10;2019:2186494. doi: 10.1155/2019/2186494. eCollection 2019.
9
Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.刺孢霉素通过诱导骨髓瘤细胞中的热休克蛋白和癌胚抗原增强树突状细胞功能。
Oncotarget. 2017 Jul 11;8(28):46047-46056. doi: 10.18632/oncotarget.17517.
10
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.骨髓微环境是骨髓瘤发生和疾病进展的关键因素。
Oncotarget. 2017 Mar 21;8(12):20394-20409. doi: 10.18632/oncotarget.14610.
自体α型 1 极化树突状细胞成功递呈同种异体骨髓瘤细胞作为匹配单克隆免疫球蛋白的骨髓瘤患者中的有效肿瘤抗原。
Ann Hematol. 2011 Dec;90(12):1419-26. doi: 10.1007/s00277-011-1219-y. Epub 2011 Apr 5.
4
Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists.I 型和 II 型干扰素通过调节 CD38 和 CD74 增强树突状细胞的成熟和迁移能力，与 TLR 激动剂具有协同作用。
Cell Mol Immunol. 2011 Jul;8(4):341-7. doi: 10.1038/cmi.2011.7. Epub 2011 Mar 21.
5
Recent developments in cancer vaccines.癌症疫苗的最新进展。
J Immunol. 2011 Feb 1;186(3):1325-31. doi: 10.4049/jimmunol.0902539.
6
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.自体独特型致敏树突状细胞瘤苗免疫治疗期Ⅰ多发性骨髓瘤患者的细胞免疫应答
J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48.
7
Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.多发性骨髓瘤患者体内 CD4+FOXP3+调节性 T 细胞和 CD14+HLA-DR⁻/low 髓系来源抑制细胞水平升高，树突状细胞水平降低。
Scand J Immunol. 2010 Dec;72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x.
8
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.树突状细胞/肿瘤融合细胞疫苗接种可诱导多发性骨髓瘤患者产生细胞和体液抗肿瘤免疫应答。
Blood. 2011 Jan 13;117(2):393-402. doi: 10.1182/blood-2010-04-277137. Epub 2010 Oct 28.
9
Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.乌卡瑞替酸 C 联合 IFN-γ 可诱导单核细胞来源的树突状细胞分化，并诱导具有迁移能力的强 Th1 极化。
Cell Immunol. 2010;266(1):104-10. doi: 10.1016/j.cellimm.2010.09.004. Epub 2010 Sep 18.
10
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.优化树突状细胞为基础的多发性骨髓瘤免疫治疗：腔内注射针对独特型的 CD40L 成熟疫苗可诱导患者产生 1 型和细胞毒性 T 细胞免疫应答。
Br J Haematol. 2010 Sep;150(5):554-64. doi: 10.1111/j.1365-2141.2010.08286.x. Epub 2010 Jul 7.